RESUMO
RESUMEN: El manejo del dolor postoperatorio en cirugía de desinclusión de terceros molares es fundamental. El uso de antiinflamatorios no esteroidales (AINES), son considerados como una excelente alternativa para el manejo del dolor, siendo administrados tanto postoperatorios, como preoperatorios. El propósito de la presente revisión bibliográfica fue establecer la eficacia y seguridad de la analgesia preoperatoria con antiinflamatorios no esteroidales en desinclusiones quirúrgicas de terceros molares en las que hubiera remoción parcial o total de hueso. Se realizó una búsqueda en las bases de datos: PubMed, EBSCO, Cochrane Library y Scielo; usando las palabras claves: Preemptive Analgesia, NSAID, Oral Surgery. Trece artículos fueron seleccionados, sumando un total de 875 pacientes evaluados. Si bien varios autores consideraron la analgesia preoperatoria con AINES, como un método eficaz, hacen falta más estudios que demuestren su eficacia en cirugía oral.
SUMMARY: The management of postoperative pain in third molar surgery is fundamental. The use of nonsteroidal antiinflammatory drugs (NSAIDs) are considered an excellent alternative for pain management, administered both, postoperative and preoperative. The purpose of this review is to establish the efficacy and safety of preemptive analgesia with nonsteroidal antiinflammatory drugs in surgical disinclusions of third molars, in which at least partial bone was removed. We conducted a search in databases like: PubMed, EBSCO, Cochrane Library and Scielo; using the key words: Preemptive Analgesia, NSAID, Oral Surgery. Thirteen articles were selected, in total of 875 patients evaluated in the selected articles. Although several authors considered preemptive analgesia with NSAIDs as an effective method, more standardized studies are needed to demonstrate its effectiveness in oral surgery.
Assuntos
Humanos , Cirurgia Bucal , Anti-Inflamatórios não Esteroides/uso terapêutico , Dente Serotino , Dor Pós-Operatória/tratamento farmacológico , Anti-Inflamatórios/uso terapêuticoRESUMO
Introducción: El tratamiento del estadio avanzado de la achalasia es un tema controvertido. Cuando el esófago adopta una morfología "sigmoidea" se ha preconizado la resección esofágica como tratamiento de elección. A la luz de los resultados recientes publicados de la cirugía laparoscópica dicha conducta debe ser revisada. Material y Método: Durante un período de 11 años se estudian los pacientes en estadio avanzado, correspondientes a nuestra serie de casos operados de achalasia de esófago, tratados con esofagectomía. Resultados: Cuatro casos intervenidos con resección esofágica, plastia gástrica, y anastomosis cervical. En tres casos por vía transhiatal y el cuarto precisó toracotomía. Edad promedio de los pacientes 63 años. Tiempo medio de duración de la sintomatología clínica 37,7 años. Morbilidad: Derrame pleural en dos casos, disfonía transitoria en dos casos, una eventración. Tras un seguimiento medio de 66 meses todos están actualmente asintomáticos.
Esophageal excisión is recommended in advanced stages of achalasia, when the esophagus acquires a sigmoid morphology. We report four patients with achalasia aged 59, 60, 66 and 67 years (two males) that were treated with esophagectomy, gastroplasty and cervical anastomosis. Three were operated using a trasnhiatal approach and one required a thoracotomy. In the postoperative period, two patients had a pleural effusion, two had transient dysphonia and one had an eventration. After a follow up ranging from two to 11 years, all are asymptomatic.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Acalasia Esofágica/cirurgia , Esofagectomia , Laparotomia , Seguimentos , Complicações Pós-OperatóriasRESUMO
A variety of eucaryotic polypeptide growth factors are synthesized as transmembrane precursors. Many of these precursors are released from plasma membranes by proteolytic cleavage and converted into soluble mature proteins. A number of studies, however, indicate that bound growth factor precursors can be biologically active, suggesting a role for these membrane-associated ligands in cell-cell communication. Secreted heregulin is a 45-kDa growth factor with homology to epidermal growth factor. This growth factor binds directly to HER-3 and HER-4 and activates heterodimeric receptor complexes composed of the type I receptor tyrosine kinases, i.e. HER-1, HER-2, HER-3, and HER-4. Heregulin was originally detected in the conditioned medium of the human breast cancer cell line MDA-MB-231 and purified based on its ability to stimulate phosphorylation of p185(HER-2/neu). In the current study, the biologic activity of plasma membrane-anchored heregulin was evaluated in human breast cells. Transmembrane heregulin binds to cells expressing p180(HER-3), induces p185(HER-2/neu) phosphorylation, and increases DNA synthesis in cells overexpressing the HER-2/neu gene product. In addition, when cells containing heregulin receptors are co-cultured with heregulin-producing cells, specific in vivo associations are observed. This study demonstrates that transmembrane heregulin is functionally active and suggest it is capable of playing a role in cell-cell communication and subsequent signal transduction in vivo.
Assuntos
Proteínas de Membrana/fisiologia , Neuregulina-1/fisiologia , Precursores de Proteínas/fisiologia , Membrana Celular/metabolismo , Imuno-Histoquímica , Fosforilação , Receptor ErbB-2/genética , Receptor ErbB-2/metabolismo , Timidina/metabolismo , Células Tumorais CultivadasRESUMO
The heregulins are a family of ligands with ability to induce phosphorylation of the p185HER-2/neu receptor. Various investigators have reported a variety of responses of mouse and human breast and ovarian cells to this family of ligands including growth stimulation, growth inhibition, apoptosis and induction of differentiation in cells expressing the HER-2/neu receptor. Some of the disparity in the literature has been attributed to variations in the cell lines studied, ligand dose applied, methodologies utilized or model system evaluated (i.e. in vitro or in vivo). To evaluate the effects of heregulin on normal and malignant human breast and ovarian epithelial cells expressing known levels of the HER-2/neu receptor, this report presents the use of several different assays, performed both in vitro and in vivo, in vitro proliferation assays, direct cell counts, clonogenicity under anchorage-dependent and anchorage-independent conditions, as well as the in vivo effects of heregulin on human cells growing in nude mice to address heregulin activity. Using a total of five different biologic assays in nine different cell lines, across two different epithelia and over a one log heregulin dose range, we obtained results that clearly indicate a growth-stimulatory role for this ligand in human breast and ovarian epithelial cells. We find no evidence that heregulin has any growth-inhibitory effects in human epithelial cells. We also quantitated the amount of each member of the type I receptor tyrosine kinase family (RTK I, i.e. HER-1, HER-2, HER-3 and HER-4) in the cell lines employed and correlated this to their respective heregulin responses. These data demonstrate that HER-2/neu overexpression itself affects the expression of other RTK I members and that cells expressing the highest levels of HER-2/neu have the greatest response to HRG.
Assuntos
Neoplasias da Mama/metabolismo , Neuregulina-1/metabolismo , Neuregulina-1/farmacologia , Neoplasias Ovarianas/metabolismo , Animais , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Testes de Carcinogenicidade , Divisão Celular/genética , Células Epiteliais/efeitos dos fármacos , Receptores ErbB/genética , Receptores ErbB/metabolismo , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Camundongos , Camundongos Nus , Neuregulina-1/genética , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/patologia , Receptor ErbB-4 , Células Tumorais CultivadasAssuntos
Administração Intranasal , Administração Oral , Administração Tópica , Inativação Metabólica , Controle de Medicamentos e Entorpecentes , Custos de Medicamentos , Monitoramento de Medicamentos , Equador , Preparações Farmacêuticas , Psicoses Induzidas por Substâncias , Receptores de Droga , Drogas Ilícitas , Centros de Tratamento de Abuso de Substâncias , Síndrome de Abstinência a Substâncias , Transtornos Relacionados ao Uso de SubstânciasRESUMO
Presenta estadísticas acerca del uso de drogas tanto legales como ilegales en el Ecuador. Proponen test para conocer el uso de drogas al interior de la familia. Muestra mapas para ubicar el tipo de drogas que son preferencia o de menor consumo en las diferentes provincias del país. Hacen una diferencia sobre los tipos de droga que se consumen en los diferentes estratos sociales...
Assuntos
Alcoolismo , Abuso de Maconha , Automedicação , Fumar , Detecção do Abuso de Substâncias , Transtornos Relacionados ao Uso de Substâncias , Portadores de FármacosAssuntos
Administração Intranasal , Administração Oral , Administração Tópica , Inativação Metabólica , Controle de Medicamentos e Entorpecentes , Custos de Medicamentos , Monitoramento de Medicamentos , Equador , Preparações Farmacêuticas , Psicoses Induzidas por Substâncias , Receptores de Droga , Drogas Ilícitas , Centros de Tratamento de Abuso de Substâncias , Síndrome de Abstinência a Substâncias , Transtornos Relacionados ao Uso de SubstânciasRESUMO
An epidemiological investigation was conducted in 1988 to measure prevalence of the improper use of alcohol, tobacco, and illegal drugs in the Ecuadorian population. This research was based on a structured survey of 185 questions that was carried out on a probabilistic random sample of 6,000 individuals representative of the country's entire population between the ages of 10 and 65. The relative frequency of the various common forms of consumption of these substances was also investigated. The highest prevalences of addiction corresponded to alcohol and tobacco (13 percent), followed by tranquilizers (0.8 percent), opiates (0.4 percent), barbiturates and marijuana (0.2 percent), and cocaine base (0.11 percent). The most common form of consumption was experimental, followed by recreational and psychopathological, as a stimulant, and as an anesthetic. Some of the substances were shown to be related to specific forms of consumption, which in the future will serve as a basis for establishing policies for prevention, treatment, and rehabilitation
Assuntos
Alcoolismo/epidemiologia , Tabagismo/epidemiologia , Tranquilizantes/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Equador , Estudos TransversaisRESUMO
Highly purified preparations of plasma membranes from control and ketoconazole-treated (1 microM, 120 h) epimastigotes of Trypanosoma cruzi have been obtained by cell disruption using abrasion with glass beads, differential centrifugation and isopycnic centrifugation in continuous, self-generating Percoll gradients. The purity of the preparation was ascertained by the specific activity 125I bound to the membranes obtained from enzymatically radiolabeled epimastigotes and by the alpha-methyl-mannoside sensitive binding of 125I-concanavalin A. The membranes form closed vesicles of 0.2-0.4 micron in diameter which display Mg2+ ATPase and acid phosphatase activities, but are devoid of 5'-nucleotidase and succinate-cytochrome c oxidoreductase; these vesicles can be strongly agglutinated by concanavalin A. The lipid order profiles of membranes from control and treated cells were compared with that present in egg phosphatidylcholine/ergosterol liposomes (84:16, mol/mol) by electron spin resonance spectroscopy of doxylstearic acid probes with the nitroxide group bound to carbon 5, 10, 12 and 16 of the stearic acid chain. Membranes from treated epimastigotes have a lipid order profile which resembles that of control plasma membranes near the polar surface (positions 5 and 10) but there is an abrupt decrease of order at position 12 and from there to the center of bilayer is highly disordered, even more than in pure lipid membranes. Consistent with these results, the leakage of L-[14C]glucose from membrane vesicles of ketoconazole-treated cells is much faster than that observed in vesicles obtained from control cells. These results indicate a strong alteration of the plasma membrane physical and biological properties due to the incubation of the parasite with the drug; this alteration is consistent with the accumulation of methylated precursors of ergosterol, which affects both lipid-lipid and lipid-protein interactions in the membrane.
Assuntos
Cetoconazol/farmacologia , Bicamadas Lipídicas/metabolismo , Lipídeos de Membrana/metabolismo , Trypanosoma cruzi/metabolismo , Animais , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Permeabilidade da Membrana Celular , Centrifugação com Gradiente de Concentração , Centrifugação Isopícnica , Espectroscopia de Ressonância de Spin Eletrônica , Microscopia Eletrônica , Trypanosoma cruzi/efeitos dos fármacos , Trypanosoma cruzi/ultraestruturaRESUMO
The phosphofructokinase (ATP:D-fructose-6-phosphate 1-phosphotransferase, E.C.2.7.1.11) of Trypanosoma (Schizotrypanum) cruzi epimastigotes has been purified 180-fold, to apparent electrophoretic homogeneity, by differential centrifugation, gel filtration chromatography and anionic exchange chromatography. The minimum catalytic unit of the purified enzyme is a polypeptide of 17,000 +/- 1300 molecular weight, as shown by gel filtration chromatography and SDS-gel electrophoresis. Hanes-Woolf plots of initial rates and Mg-ATP or D-fructose-6-phosphate concentrations for varying values of the co-substrate concentration gave intersecting lines which indicate a sequential mechanism. No inhibition is observed at high Mg-ATP concentrations, confirming the result of a previous study using a partially purified enzyme. The pure enzyme displays both negative and positive cooperative kinetics at low (less than 0.8 mM) concentrations of D-fructose-6-phosphate, suggesting aggregation and/or activation phenomena induced by this substrate. Product inhibition studies at saturating and non-saturating concentrations of D-fructose-6-phosphate gave as the only compatible mechanism an iso-ordered bi-bi process with a probable order of entry to and exit from the active site being: D-fructose-6-phosphate followed by Mg-ATP and D-fructose-1,6-bisphosphate followed by Mg-ADP, respectively. The very important differences in both the structural and mechanistic aspects between this enzyme and its vertebrate and bacterial counterparts supports the notion of a highly unusual carbohydrate catabolism in this parasite.
Assuntos
Fosfofrutoquinase-1/isolamento & purificação , Trypanosoma cruzi/enzimologia , Animais , Cromatografia em Gel , Cromatografia por Troca Iônica , Eletroforese em Gel de Poliacrilamida , Cinética , Peso Molecular , Fosfofrutoquinase-1/metabolismoRESUMO
The contents of this special issue were also published in Spanish in the Boletín de la Oficina Sanitaria Panamericana Vol. 107, N0. 6, 1989
Assuntos
Transtornos Relacionados ao Uso de Substâncias , Alcoolismo , Fumar , Cocaína , Tranquilizantes , Estudos Transversais , EquadorRESUMO
An epidemiological investigation was conducted in 1988 to measure prevalence of the improper use of alcohol, tobacco, and illegal drugs in the Ecuadorian population. This research was based on a structured survey of 185 questions that was carried out on a probabilistic random sample of 6,000 individuals representative of the country's entire population between the ages of 10 and 65. The relative frequency of the various common forms of consumption of these substances was also investigated. The highest prevalences of addiction corresponded to alcohol and tobacco (13 percent), followed by tranquilizers (0.8 percent), opiates (0.4 percent), barbiturates and marijuana (0.2 percent), and cocaine base (0.11 percent). The most common form of consumption was experimental, followed by recreational and psychopathological, as a stimulant, and as an anesthetic. Some of the substances were shown to be related to specific forms of consumption, which in the future will serve as a basis for establishing policies for prevention, treatment, and rehabilitation